Steph & Co. Grows Position in ICON Public Limited (NASDAQ:ICLR)

Steph & Co. boosted its position in ICON Public Limited (NASDAQ:ICLR) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,560 shares of the medical research company’s stock after purchasing an additional 55 shares during the quarter. Steph & Co.’s holdings in ICON Public were worth $327,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ICLR. Icon Wealth Advisors LLC grew its stake in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the last quarter. Foyston Gordon & Payne Inc purchased a new stake in shares of ICON Public in the third quarter worth $11,672,000. GAMMA Investing LLC increased its holdings in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Sara Bay Financial purchased a new position in shares of ICON Public in the 3rd quarter worth about $1,143,000. Finally, First Horizon Advisors Inc. boosted its stake in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Trading Down 0.4 %

Shares of ICLR stock opened at $199.47 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The company has a market cap of $16.46 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.59 and a beta of 1.20. ICON Public Limited has a 1 year low of $183.38 and a 1 year high of $347.72. The firm has a fifty day moving average price of $210.30 and a 200-day moving average price of $269.51.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the firm posted $3.10 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts predict that ICON Public Limited will post 13.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ICLR has been the subject of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research note on Wednesday. Robert W. Baird decreased their price objective on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, Evercore ISI dropped their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.